The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.
Stocktwits on MSN
Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results
An investigational intravesical drug-releasing system with erdafitinib is designed to provide prolonged release of erdafitinib directly into the bladder via intravesical administration. ・The company ...
Zacks Investment Research on MSN
JNJ's bladder cancer therapy meets key goal in early-stage study
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...
Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results